Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 15
April 12 2018
Issue Cover

Table of Contents

EDITORIAL

Introduction to a review series on Hodgkin lymphoma: change is here
Clinical Trials & Observations
Laurie H. Sehn
View Articletitled, Introduction to a review series on Hodgkin lymphoma: change is here

BLOOD COMMENTARIES

MYELOID NEOPLASIA
Metabolic strugGLS after FLT3 inhibition in AML
Samuel J. Taylor,Ulrich Steidl
View Articletitled, Metabolic strugGLS after FLT3 inhibition in AML
CLINICAL TRIALS AND OBSERVATIONS
Venetoclax after idelalisib: relevant progress for CLL
Clinical Trials & Observations
Francesc Bosch,Michael Hallek
View Articletitled, Venetoclax after idelalisib: relevant progress for CLL
Hematopoiesis and Stem Cells
Can genetics resolve what Notch does in HSCs?
Ivan Maillard,Warren S. Pear
View Articletitled, Can genetics resolve what Notch does in HSCs?
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Lymphoma exosomes reprogram the bone marrow
Theresa L. Whiteside
View Articletitled, Lymphoma exosomes reprogram the bone marrow
TRANSPLANTATION
Chemokines: a novel chronic GVHD target
Carrie Kitko,John E. Levine
View Articletitled, Chemokines: a novel chronic GVHD target

PLENARY PAPER

MYELOID NEOPLASIA
Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
Paolo Gallipoli,George Giotopoulos,Konstantinos Tzelepis,Ana S. H. Costa,Shabana Vohra,Paula Medina-Perez,Faisal Basheer,Ludovica Marando,Lorena Di Lisio,Joao M. L. Dias,Haiyang Yun,Daniel Sasca,Sarah J. Horton,George Vassiliou,Christian Frezza,Brian J. P. Huntly
View Articletitled, Glutaminolysis is a metabolic dependency in FLT3<sup>ITD</sup> acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
Supplemental data

REVIEW SERIES

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
Anja Mottok,Christian Steidl
View Articletitled, Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
Balancing risk and benefit in early-stage classical Hodgkin lymphoma
Clinical Trials & Observations
Paul J. Bröckelmann,Stephanie Sasse,Andreas Engert
View Articletitled, Balancing risk and benefit in early-stage classical Hodgkin lymphoma
Optimizing therapy in advanced-stage Hodgkin lymphoma
Clinical Trials & Observations
Sean H. Lim,Peter W. M. Johnson
View Articletitled, Optimizing therapy in advanced-stage Hodgkin lymphoma
Transplant strategies in relapsed/refractory Hodgkin lymphoma
Gunjan L. Shah,Craig H. Moskowitz
View Articletitled, Transplant strategies in relapsed/refractory Hodgkin lymphoma
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients
Clinical Trials & Observations
Neha Mehta-Shah,Nancy L. Bartlett
View Articletitled, Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

CLINICAL TRIALS AND OBSERVATIONS

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Clinical Trials & Observations
Steven Coutre,Michael Choi,Richard R. Furman,Herbert Eradat,Leonard Heffner,Jeffrey A. Jones,Brenda Chyla,Lang Zhou,Suresh Agarwal,Tina Waskiewicz,Maria Verdugo,Rod A. Humerickhouse,Jalaja Potluri,William G. Wierda,Matthew S. Davids
View Articletitled, Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Canonical Notch signaling is dispensable for adult steady-state and stress myelo-erythropoiesis
Sara Duarte,Petter S. Woll,Natalija Buza-Vidas,Desmond Wai Loon Chin,Hanane Boukarabila,Tiago C. Luís,Laura Stenson,Tiphaine Bouriez-Jones,Helen Ferry,Adam J. Mead,Deborah Atkinson,Shaobo Jin,Sally-Ann Clark,Bishan Wu,Emmanouela Repapi,Nicki Gray,Stephen Taylor,Anders P. Mutvei,Yat Long Tsoi,Claus Nerlov,Urban Lendahl,Sten Eirik W. Jacobsen
View Articletitled, Canonical Notch signaling is dispensable for adult steady-state and stress myelo-erythropoiesis
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling
Mateja Manček-Keber,Duško Lainšček,Mojca Benčina,Jiaji G. Chen,Rok Romih,Zachary R. Hunter,Steven P. Treon,Roman Jerala
View Articletitled, Extracellular vesicle–mediated transfer of constitutively active MyD88<sup>L265P</sup> engages MyD88<sup>wt</sup> and activates signaling
Supplemental data

MYELOID NEOPLASIA

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML
Monica Cusan,Sheng F. Cai,Helai P. Mohammad,Andrei Krivtsov,Alan Chramiec,Evangelia Loizou,Matthew D. Witkin,Kimberly N. Smitheman,Daniel G. Tenen,Min Ye,Britta Will,Ulrich Steidl,Ryan G. Kruger,Ross L. Levine,Hugh Y. Rienhoff, Jr,Richard P. Koche,Scott A. Armstrong
View Articletitled, LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML
Supplemental data

TRANSPLANTATION

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients
Jing Du,Ryan Flynn,Katelyn Paz,Hong-Gang Ren,Yuko Ogata,Qing Zhang,Philip R. Gafken,Barry E. Storer,Nathan H. Roy,Janis K. Burkhardt,Wendy Mathews,Jakub Tolar,Stephanie J. Lee,Bruce R. Blazar,Sophie Paczesny
View Articletitled, Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients
Supplemental data

LETTERS TO BLOOD

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia
Simon Schliffke,Sophia Buhs,Sarah Bolz,Helwe Gerull,Lisa von Wenserski,Kristoffer Riecken,Boris Fehse,Peter Nollau,Mascha Binder
View Articletitled, The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia
Supplemental data
A Ser725Arg mutation in Band 3 abolishes transport function and leads to anemia and renal tubular acidosis
Elizabeth Yang,Patricia Seo-Mayer,Kimberly Lezon-Geyda,Katherine E. Badior,Jing Li,Joseph R. Casey,Reinhart A. F. Reithmeier,Patrick G. Gallagher
View Articletitled, A Ser725Arg mutation in Band 3 abolishes transport function and leads to anemia and renal tubular acidosis

BLOOD WORK

ALK+ small cell variant of anaplastic large cell lymphoma with leukemic presentation
Xianyong Jiang,Daobin Zhou
View Articletitled, ALK<sup>+</sup> small cell variant of anaplastic large cell lymphoma with leukemic presentation
Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system
Yasushi Kubota,Kana Kusaba
View Articletitled, Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system
All Issues

Advertisement intended for health care professionals

Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias
Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort
GVHD targets organoid-forming bile duct stem cells via a TGF-β-dependent manner
Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART) therapy in children and adolescents
How I Treat on Infant Acute Lymphoblastic Leukemia

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals